Literature DB >> 19275708

Drug targets in severe acute respiratory syndrome (SARS) virus and other coronavirus infections.

Tommy R Tong1.   

Abstract

Coronaviruses are important human and animal pathogens of the order Nidovirales. Several new members were discovered following the emergence of SARS-CoV in human populations, including two human coronaviruses and several animal coronaviruses. They cause respiratory and gastrointestinal illnesses and have been found in the brains of patients with multiple sclerosis. The high mortality of SARS, the identification of a natural reservoir, and the well-founded fear of provoking antibody-enhanced disease as a result of vaccination fueled the ongoing efforts in anti-coronavirus drug discovery. This review presents the results of current research.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19275708     DOI: 10.2174/187152609787847659

Source DB:  PubMed          Journal:  Infect Disord Drug Targets        ISSN: 1871-5265


  19 in total

1.  Cyclosporin A inhibits the replication of diverse coronaviruses.

Authors:  Adriaan H de Wilde; Jessika C Zevenhoven-Dobbe; Yvonne van der Meer; Volker Thiel; Krishna Narayanan; Shinji Makino; Eric J Snijder; Martijn J van Hemert
Journal:  J Gen Virol       Date:  2011-07-13       Impact factor: 3.891

2.  Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.

Authors:  Prasenjit Mukherjee; Falgun Shah; Prashant Desai; Mitchell Avery
Journal:  J Chem Inf Model       Date:  2011-05-23       Impact factor: 4.956

3.  Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.

Authors:  Adriaan H de Wilde; Dirk Jochmans; Clara C Posthuma; Jessika C Zevenhoven-Dobbe; Stefan van Nieuwkoop; Theo M Bestebroer; Bernadette G van den Hoogen; Johan Neyts; Eric J Snijder
Journal:  Antimicrob Agents Chemother       Date:  2014-05-19       Impact factor: 5.191

4.  Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.

Authors:  Dale L Barnard; Yohichi Kumaki
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

5.  Identification and evaluation of potential SARS-CoV-2 antiviral agents targeting mRNA cap guanine N7-Methyltransferase.

Authors:  Renata Kasprzyk; Tomasz J Spiewla; Miroslaw Smietanski; Sebastian Golojuch; Laura Vangeel; Steven De Jonghe; Dirk Jochmans; Johan Neyts; Joanna Kowalska; Jacek Jemielity
Journal:  Antiviral Res       Date:  2021-07-23       Impact factor: 5.970

6.  X-ray structural and biological evaluation of a series of potent and highly selective inhibitors of human coronavirus papain-like proteases.

Authors:  Yahira M Báez-Santos; Scott J Barraza; Michael W Wilson; Michael P Agius; Anna M Mielech; Nicole M Davis; Susan C Baker; Scott D Larsen; Andrew D Mesecar
Journal:  J Med Chem       Date:  2014-03-14       Impact factor: 7.446

Review 7.  The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.

Authors:  Yahira M Báez-Santos; Sarah E St John; Andrew D Mesecar
Journal:  Antiviral Res       Date:  2014-12-29       Impact factor: 5.970

Review 8.  Is multiple sclerosis a mitochondrial disease?

Authors:  Peizhong Mao; P Hemachandra Reddy
Journal:  Biochim Biophys Acta       Date:  2009-07-14

9.  Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus.

Authors:  Sivakoteswara Rao Mandadapu; Pathum M Weerawarna; Allan M Prior; Roxanne Adeline Z Uy; Sridhar Aravapalli; Kevin R Alliston; Gerald H Lushington; Yunjeong Kim; Duy H Hua; Kyeong-Ok Chang; William C Groutas
Journal:  Bioorg Med Chem Lett       Date:  2013-05-16       Impact factor: 2.823

Review 10.  COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach.

Authors:  Soha R Abd El Hadi; Esmat E Zien El-Deen; Mostafa M Bahaa; Abdelfattah A Sadakah; Heba A Yassin
Journal:  Drug Des Devel Ther       Date:  2021-07-30       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.